DE3875852T2 - Gereinigtes igm. - Google Patents
Gereinigtes igm.Info
- Publication number
- DE3875852T2 DE3875852T2 DE8888111931T DE3875852T DE3875852T2 DE 3875852 T2 DE3875852 T2 DE 3875852T2 DE 8888111931 T DE8888111931 T DE 8888111931T DE 3875852 T DE3875852 T DE 3875852T DE 3875852 T2 DE3875852 T2 DE 3875852T2
- Authority
- DE
- Germany
- Prior art keywords
- igm
- preparation according
- less
- nucleic acid
- acid content
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000002360 preparation method Methods 0.000 claims abstract description 31
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 26
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 26
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 26
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims abstract description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 28
- 239000011780 sodium chloride Substances 0.000 claims description 14
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 12
- 150000001720 carbohydrates Chemical class 0.000 claims description 7
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 6
- 239000004471 Glycine Substances 0.000 claims description 6
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 6
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 6
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 3
- 239000008121 dextrose Substances 0.000 claims description 3
- 244000005700 microbiome Species 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- 239000000427 antigen Substances 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 230000000087 stabilizing effect Effects 0.000 claims 2
- 230000001717 pathogenic effect Effects 0.000 claims 1
- 238000001542 size-exclusion chromatography Methods 0.000 abstract description 3
- 238000004255 ion exchange chromatography Methods 0.000 abstract description 2
- 238000000034 method Methods 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 10
- 239000000047 product Substances 0.000 description 9
- 239000000872 buffer Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 6
- 239000007983 Tris buffer Substances 0.000 description 5
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 239000012228 culture supernatant Substances 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 102000009027 Albumins Human genes 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 3
- 206010003445 Ascites Diseases 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000013020 final formulation Substances 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000012264 purified product Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 1
- 101000766306 Homo sapiens Serotransferrin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 102000005686 Serum Globulins Human genes 0.000 description 1
- 108010045362 Serum Globulins Proteins 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000008570 general process Effects 0.000 description 1
- 210000004754 hybrid cell Anatomy 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1214—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Public Health (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Saccharide Compounds (AREA)
- Detergent Compositions (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8313687A | 1987-08-10 | 1987-08-10 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE3875852D1 DE3875852D1 (de) | 1992-12-17 |
| DE3875852T2 true DE3875852T2 (de) | 1993-03-18 |
Family
ID=22176414
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE8888111931T Expired - Lifetime DE3875852T2 (de) | 1987-08-10 | 1988-07-25 | Gereinigtes igm. |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP0303088B1 (enExample) |
| JP (1) | JP2730913B2 (enExample) |
| AT (1) | ATE82136T1 (enExample) |
| AU (1) | AU618745B2 (enExample) |
| CA (1) | CA1341474C (enExample) |
| DE (1) | DE3875852T2 (enExample) |
| ES (1) | ES2045027T3 (enExample) |
| GR (1) | GR3006536T3 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01197500A (ja) * | 1988-01-29 | 1989-08-09 | Sumitomo Chem Co Ltd | ヒトモノクローナル抗体 |
| DE3825429C2 (de) * | 1988-07-27 | 1994-02-10 | Biotest Pharma Gmbh | Verfahren zur Herstellung eines intravenös verabreichbaren polyklonalen Immunglobulin-Präparates mit hohem IgM-Gehalt |
| EP0382031A3 (en) * | 1989-02-10 | 1991-06-26 | Miles Inc. | Monoclonal antibodies in immune serum globulin |
| CA2049342A1 (en) * | 1989-03-27 | 1990-09-28 | Sally Bolmer | Formulations for stabilizing of igm antibodies |
| HUT63343A (en) * | 1990-07-03 | 1993-08-30 | Akzo Nv | Process for producing immunereactive compounds |
| JPH0565233A (ja) * | 1991-03-08 | 1993-03-19 | Mitsui Toatsu Chem Inc | モノクローナル抗体含有凍結乾燥製剤 |
| EP0852951A1 (de) | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern |
| ATE414537T1 (de) | 2001-08-29 | 2008-12-15 | Chugai Pharmaceutical Co Ltd | Antikörper enthaltende stabilisierte zubereitungen |
| EP1652925B1 (en) | 2003-07-15 | 2010-12-08 | Chugai Seiyaku Kabushiki Kaisha | IgM PRODUCTION BY TRANSFORMED CELLS AND METHODS FOR QUANTIFYING SAID IgM PRODUCTION |
| JP4762717B2 (ja) * | 2003-10-09 | 2011-08-31 | 中外製薬株式会社 | ＩｇＭ高濃度安定化溶液 |
| JP4671864B2 (ja) | 2003-10-09 | 2011-04-20 | 中外製薬株式会社 | タンパク質溶液の安定化方法 |
| CA2788527A1 (en) * | 2010-01-29 | 2011-08-04 | Axis Inc. | Pharmaceutical composition for osteoarthritis treatment or prevention and manufacturing method therefor |
| US10570194B2 (en) | 2015-08-06 | 2020-02-25 | Grifols Worldwide Operations Limited | Method for treating infectious diseases using a composition comprising plasma-derived immunoglobulin M (IgM) |
| US20240417445A1 (en) * | 2023-06-13 | 2024-12-19 | Grifols Worldwide Operations Limited | Method for producing a lyophilized composition comprising polyclonal igm and composition obtained |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4604235A (en) * | 1984-05-23 | 1986-08-05 | J. T. Baker Chemical Company | Purification of monoclonal antibodies |
| US4834975A (en) * | 1984-05-25 | 1989-05-30 | Genetics Corporation | Human monoclonal antibodies to serotypic lipopolysaccharide determinants on gram-negative bacteria and their production |
| JPH0669961B2 (ja) * | 1984-09-25 | 1994-09-07 | 株式会社ミドリ十字 | 免疫グロブリンの加熱処理方法 |
-
1988
- 1988-07-25 AT AT88111931T patent/ATE82136T1/de not_active IP Right Cessation
- 1988-07-25 ES ES88111931T patent/ES2045027T3/es not_active Expired - Lifetime
- 1988-07-25 EP EP88111931A patent/EP0303088B1/en not_active Expired - Lifetime
- 1988-07-25 DE DE8888111931T patent/DE3875852T2/de not_active Expired - Lifetime
- 1988-08-02 AU AU20315/88A patent/AU618745B2/en not_active Expired
- 1988-08-09 CA CA000574199A patent/CA1341474C/en not_active Expired - Fee Related
- 1988-08-09 JP JP63197281A patent/JP2730913B2/ja not_active Expired - Lifetime
-
1992
- 1992-12-14 GR GR920402910T patent/GR3006536T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP0303088A3 (en) | 1989-05-17 |
| CA1341474C (en) | 2005-03-08 |
| JP2730913B2 (ja) | 1998-03-25 |
| GR3006536T3 (enExample) | 1993-06-30 |
| ES2045027T3 (es) | 1994-01-16 |
| EP0303088A2 (en) | 1989-02-15 |
| AU2031588A (en) | 1989-06-08 |
| DE3875852D1 (de) | 1992-12-17 |
| AU618745B2 (en) | 1992-01-09 |
| EP0303088B1 (en) | 1992-11-11 |
| ATE82136T1 (de) | 1992-11-15 |
| JPH02493A (ja) | 1990-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69223641T2 (de) | Stabilisierte antikörper | |
| DE69735295T2 (de) | Verfahren zur Aufkonzentrierung von Antikörperlösungen | |
| DE3875852T2 (de) | Gereinigtes igm. | |
| DE68929061T2 (de) | Herstellung humanähnlicher Immunoglobuline und entsprechender Polynukleotide | |
| DE69232617T2 (de) | Gefriergetrocknete Zubereitung, die einen monoklonalen Antikörper enthält | |
| DE69228474T2 (de) | STABILISIERTE AUFBEREITUNG MONOKLONALER MENSCHLICHER CLN-IgG ANTIKÖRPER | |
| DE69128774T2 (de) | GEREINIGTE IgG ANTIKÖRPER | |
| DE4118912C1 (enExample) | ||
| EP0659767B2 (de) | Verfahren zur Herstellung eines Konzentrates von Anti-D-Immunoglobulin G und pharmazeutische Zusammensetzung, die dieses enthält | |
| EP0260610A2 (de) | Monoklonale Antikörper gegen humanen Tumonekrosefaktor (TNF) und deren Verwendung | |
| DE2826075C2 (enExample) | ||
| DE69333447T2 (de) | Antikörper mit spezifikäten gegen mehrere adhäsionsmoleküle | |
| DE68918673T2 (de) | IgG-bindendes Protein H, kodierendes Gen dafür und Verfahren zu seiner Herstellung. | |
| DE69028095T2 (de) | M-csf-monoklonale antikörper, die ein neutralisierendes konformationales epitop erkennen | |
| DE3939706C1 (enExample) | ||
| EP0085747B2 (de) | Intravenös verabreichbares humanes Immunglobulin und Verfahren zu dessen Herstellung | |
| DE69430846T2 (de) | Für natürliche killerzellen spezifische antigene und sie identifizierende antikörper | |
| DE68917338T2 (de) | Monoklonaler Antikörper mit selektiver Bindung an ein neues g-csf-Derivat. | |
| CH684164A5 (de) | Intravenös anwendbare Immunglobulinlösung. | |
| DE3752184T2 (de) | Herstellung und Verwendungen von gamma-Interferon | |
| DE69126727T2 (de) | Warm-behandelte IGM-Antikörper-Zusammensetzungen | |
| DE68907933T2 (de) | Therapeutisches Mittel für Thrombocytopenia. | |
| DE3852236T2 (de) | Verfahren zur Kontrolle der Leukozyten-Extravasation. | |
| DE3539775C2 (de) | Neues Lymphokin, gegen dieses Lymphokin spezifische Antikörper, Verfahren zu ihrer Herstellung und ihre Verwendung | |
| DE3413342A1 (de) | Gegen pilze der gattung aspergillus gerichtete antikoerper |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |